Skip to main content
. 2018 Jul 30;119(5):565–571. doi: 10.1038/s41416-018-0190-y

Fig. 2.

Fig. 2

CONSORT trial flow diagram for patients with partially platinum-sensitive ovarian cancer who were accrued into the Trabectedin Arm